Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 75
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 44
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 299-314
Open Access | Times Cited: 19
Janus kinase inhibitors for alopecia areata
Brett King, Brittany G. Craiglow
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 2, pp. S29-S32
Open Access | Times Cited: 34
Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments
Karolina Makowska, Joanna Nowaczyk, Leszek Blicharz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 781-781
Open Access | Times Cited: 33
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
Athimalaipet V Ramanan, Pierre Quartier, Nami Okamoto, et al.
The Lancet (2023) Vol. 402, Iss. 10401, pp. 555-570
Closed Access | Times Cited: 32
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 24
Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Maryanne M. Senna, Arash Mostaghimi, Manabu Ohyama, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 3, pp. 583-593
Open Access | Times Cited: 13
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 11
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, et al.
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 30
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cédric J. Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 20
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
Dionysis Nikolopoulos, Ioannis Parodis
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 15
Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
J Zhang, Wenhui Li, Mingli Gong, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study
Ida Vittrup, David Thein, Simon Francis Thomsen, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv18638-adv18638
Open Access | Times Cited: 4
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. 784-801
Open Access | Times Cited: 8
Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
Andrea Sechi, Junhyuk Song, Massimo Dell’Antonia, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 8, pp. 1535-1546
Open Access | Times Cited: 7
Baricitinib as the first systemic treatment for severe alopecia areata
Colin Kincaid, Justin D. Arnold, Natasha Atanaskova Mesinkovska
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 6, pp. 565-573
Closed Access | Times Cited: 7
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
Rieke Alten, Gerd R Burmester, Marco Matucci‐Cerinic, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 6, pp. 1575-1595
Open Access | Times Cited: 6
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward
Narendra Kumar Bagri, Christine Chew, Athimalaipet V Ramanan
Pediatric Drugs (2023) Vol. 25, Iss. 6, pp. 635-647
Closed Access | Times Cited: 6
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib
Flaminia Antonelli, Dalma Malvaso, Giacomo Caldarola, et al.
Immunotherapy (2023) Vol. 15, Iss. 18, pp. 1521-1529
Closed Access | Times Cited: 5
Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study
Qing Yan, Jianwen Liu, Xianming Long, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 10, pp. 3139-3145
Closed Access | Times Cited: 1
[Artículo traducido] Perfil de seguridad a largo plazo y usos fuera de indicación de los inhibidores de JAK en dermatología
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. T784-T801
Open Access | Times Cited: 4
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
Eric F. Morand, Josef S Smolen, Michelle Petri, et al.
RMD Open (2023) Vol. 9, Iss. 3, pp. e003302-e003302
Open Access | Times Cited: 4
Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Axel De Greef, Romane Thirion, Pierre‐Dominique Ghislain, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2869-2877
Open Access | Times Cited: 4
Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Eleftheria Tampouratzi, Konstantinos Sfaelos, Maria Pizimola, et al.
(2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top